Rating scales for behavioral symptoms in Huntington's disease: Critique and recommendations

Movement Disorders

Volumn 31, Issue 10, 2016, Pages 1466-1478

  Mestre, Tiago A ^a   van Duijn, Erik ^b   Davis, Aileen M ^c   Bachoud Lévi, Anne Catherine ^d   Busse, Monica ^e   Anderson, Karen E ^f   Ferreira, Joaquim J ^g   Mahlknecht, Philipp ^h   Tumas, Vitor ⁱ   Sampaio, Cristina ^j   Goetz, Chris G ^k   Cubo, Esther ^l   Stebbins, Glenn T ^k   Martinez Martin, Pablo ^m  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e CARDIFF UNIVERSITY   (United Kingdom)

^f GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF LISBON   (Portugal)

^h INNSBRUCK MEDICAL UNIVERSITY   (Austria)

ⁱ UNIVERSITY OF SÃO PAULO   (Brazil)

^j CHDI MANAGEMENT CHDI FOUNDATION   (United States)

^k RUSH UNIVERSITY MEDICAL CENTER   (United States)

^l HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^m INSTITUTO DE SALUD CARLOS III   (Spain)

more..

Author keywords

anxiety; behavior; depression; Huntington's disease; irritability; rating scales

Indexed keywords

ANXIETY DISORDER; APATHY; APATHY EVALUATION SCALE; APATHY SCALE; APATHY SUBSCALE OF THE FRONTAL SYSTEMS BEHAVIOR SCALE; BECK DEPRESSION INVENTORY; BEHAVIOR ASSESSMENT; BEHAVIOR DISORDER; CLINICAL ASSESSMENT; COMPULSION; DEPRESSION; DEPRESSION INTENSITY SCALE CIRCLES; DISEASE SEVERITY; DSM-IV; HAMILTON ANXIETY SCALE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; HUNTINGTON CHOREA; IRRITABILITY; IRRITABILITY APATHY SCALE; IRRITABILITY SCALE; IRRITABILITY SCALE FOR IRRITABILITY; IRRITABILITY, DEPRESSION, AND ANXIETY SCALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PRIORITY JOURNAL; PROBLEM BEHAVIORS ASSESSMENT FOR HUNTINGTON DISEASE SHORT FORM; PSYCHOSIS; REVIEW; SCHEDULE OF COMPULSIONS, OBSESSIONS AND PATHOLOGICAL IMPULSES; STATE TRAIT ANXIETY INVENTORY; SUICIDAL IDEATION; SYSTEMATIC REVIEW; UNIFIED HUNTINGTON DISEASE RATING SCALE; VALIDATION STUDY;

EID: 84991236956     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26675     Document Type: Review

References (87)

1. Orth M, European Huntington's Disease N, Handley OJ, et al. Observing Huntington's disease: the European Huntington's Disease Network's REGISTRY. J Neurol Neurosurg Psychiatry 2011;82:1409-1412.
2. van Duijn E, Reedeker N, Giltay EJ, Eindhoven D, Roos RA, van der Mast RC. Course of irritability, depression and apathy in Huntington's disease in relation to motor symptoms during a two-year follow-up period. Neurodegener Dis 2014;13:9-16.
3. Paulsen JS, Long JD, Ross CA, et al. Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational study. Lancet Neurol 2014;13:1193-1201.
4. Ho AK, Gilbert AS, Mason SL, Goodman AO, Barker RA. Health-related quality of life in Huntington's disease: Which factors matter most? Mov Disord 2009;24:574-578.
5. Moulton CD, Hopkins CW, Bevan-Jones WR. Systematic review of pharmacological treatments for depressive symptoms in Huntington's disease. Mov Disord 2014;29:1556-1561.
6. Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C. Therapeutic interventions for symptomatic treatment in Huntington's disease. Cochrane Database Syst Rev 2009:CD006456.
7. van Duijn E, Craufurd D, Hubers AA, et al. Neuropsychiatric symptoms in a European Huntington's disease cohort (REGISTRY). J Neurol Neurosurg Psychiatry 2014;85:1411-1418.
8. Schrag A, Barone P, Brown RG, et al. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord 2007;22:1077-1092.
9. Kloppel S, Stonnington CM, Petrovic P, et al. Irritability in pre-clinical Huntington's disease. Neuropsychologia 2010;48:549-557.
10. National Institute of Neurological Disorders and Stroke (NINDS). NINDS Common Data Elements Notice of Copyright, Irritability Scale. Available at: https://commondataelements.ninds.nih.gov/Doc/NOC/Irritability_Scale_NOC_Email.pdf. Accessed November 12, 2015.
11. Chatterjee A, Anderson KE, Moskowitz CB, Hauser WA, Marder KS. A comparison of self-report and caregiver assessment of depression, apathy, and irritability in Huntington's disease. J Neuropsychiatry Clin Neurosci 2005;17:378-383.
12. Reedeker N, Bouwens JA, Giltay EJ, et al. Irritability in Huntington's disease. Psychiatry Res 2012;200:813-818.
13. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-55.
14. Leroi I, O'Hearn E, Marsh L, et al. Psychopathology in patients with degenerative cerebellar diseases: a comparison to Huntington's disease. Am J Psychiatry 2002;159:1306-1314.
15. Lucetti C, Del Dotto P, Gambaccini G, et al. IV amantadine improves chorea in Huntington's disease: an acute randomized, controlled study. Neurology 2003;60:1995-1997.
16. Zappacosta B, Monza D, Meoni C, et al. Psychiatric symptoms do not correlate with cognitive decline, motor symptoms, or CAG repeat length in Huntington's disease. Arch Neurol 1996;53:493-497.
17. Spielberger CD, Sydeman SJ. State-Trait Anxiety Inventory and State-Trait Anger Expression Inventory. In: Maruish ME, ed. The Use of Psychological Testing for Treatment Planning and Outcome Assessment. Hillsdale, NJ: Hove: L. Erlbaum Associates; 1994.
18. Gargiulo M, Lejeune S, Tanguy ML, et al. Long-term outcome of presymptomatic testing in Huntington disease. Eur J Hum Genet 2009;17:165-171.
19. Nimmagadda SR, Agrawal N, Worrall-Davies A, Markova I, Rickards H. Determinants of irritability in Huntington's disease. Acta Neuropsychiatr 2011;23:309-314.
20. Decruyenaere M, Evers-Kiebooms G, Boogaerts A, et al. Prediction of psychological functioning one year after the predictive test for Huntington's disease and impact of the test result on reproductive decision making. J Med Genet 1996;33:737-743.
21. Horowitz MJ, Field NP, Zanko A, Donnelly EF, Epstein C, Longo F. Psychological impact of news of genetic risk for Huntington disease. Am J Med Genet 2001;103:188-192.
22. De Souza J, Jones LA, Rickards H. Validation of self-report depression rating scales in Huntington's disease. Mov Disord 2010;25:91-96.
23. Bachoud-Levi AC, Maison P, Bartolomeo P, et al. Retest effects and cognitive decline in longitudinal follow-up of patients with early HD. Neurology 2001;56:1052-1058.
24. Baudic S, Maison P, Dolbeau G, et al. Cognitive impairment related to apathy in early Huntington's disease. Dement Geriatr Cogn Disord 2006;21:316-321.
25. Lundervold AJ, Reinvang I. Neuropsychological findings and depressive symptoms in patients with Huntington's disease. Scand J Psychol 1991;32:275-283.
26. Sitek EJ, Soltan W, Robowski P, Schinwelski M, Wieczorek D, Slawek J. Poor insight into memory impairment in patients with Huntington disease. Neurol Neurochir Pol 2012;46:318-325.
27. Sitek EJ, Soltan W, Wieczorek D, et al. Self-awareness of executive dysfunction in Huntington's disease: comparison with Parkinson's disease and cervical dystonia. Psychiatry Clin Neurosci 2013;67:59-62.
28. Brugger F, Hepperger C, Hametner EM, et al. [Predictors of mental and physical quality of life in Huntington's disease]. Nervenarzt 2015;86:167-173.
29. Banaszkiewicz K, Sitek EJ, Rudzinska M, Soltan W, Slawek J, Szczudlik A. Huntington's disease from the patient, caregiver and physician's perspectives: three sides of the same coin? J Neural Transm 2012;119:1361-1365.
30. Beglinger LJ, Adams WH, Langbehn D, et al. Results of the citalopram to enhance cognition in Huntington disease trial. Mov Disord 2014;29:401-405.
31. Como PG, Rubin AJ, O'Brien CF, et al. A controlled trial of fluoxetine in nondepressed patients with Huntington's disease. Mov Disord 1997;12:397-401.
32. Vitale C, Marconi S, Di Maio L, et al. Short-term continuous infusion of apomorphine hydrochloride for treatment of Huntington's chorea: A double blind, randomized cross-over trial. Mov Disord 2007;22:2359-2364.
33. Holl AK, Wilkinson L, Painold A, Holl EM, Bonelli RM. Combating depression in Huntington's disease: effective antidepressive treatment with venlafaxine XR. Int Clin Psychopharmacol 2010;25:46-50.
34. Brusa L, Orlacchio A, Moschella V, Iani C, Bernardi G, Mercuri NB. Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine. Mov Disord 2009;24:126-129.
35. Rickards H, De Souza J, Crooks J, et al. Discriminant analysis of Beck Depression Inventory and Hamilton Rating Scale for Depression in Huntington's disease. J Neuropsychiatry Clin Neurosci 2011;23:399-402.
36. Starkstein SE, Mayberg HS, Preziosi TJ, Andrezejewski P, Leiguarda R, Robinson RG. Reliability, validity, and clinical correlates of apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1992;4:134-139.
37. Reedeker N, Van Der Mast RC, Giltay EJ, Van Duijn E, Roos RA. Hypokinesia in Huntington's disease co-occurs with cognitive and global dysfunctioning. Mov Disord 2010;25:1612-1618.
38. van Duijn E, Giltay EJ, Zitman FG, Roos RA, van der Mast RC. Measurement of psychopathology in Huntington's disease: the critical role of caregivers. J Nerv Ment Dis 2010;198:329-333.
39. Hubers AA, Reedeker N, Giltay EJ, Roos RA, van Duijn E, van der Mast RC. Suicidality in Huntington's disease. J Affect Disord 2012;136:550-557.
40. van Duijn E, Reedeker N, Giltay EJ, Roos RA, van der Mast RC. Correlates of apathy in Huntington's disease. J Neuropsychiatry Clin Neurosci 2010;22:287-294.
41. Stout JC, Ready RE, Grace J, Malloy PF, Paulsen JS. Factor Analysis of the Frontal Systems Behavior Scale (FrSBe). Assessment 2003;10:79-85.
42. Duff K, Paulsen JS, Beglinger LJ, et al. “Frontal” behaviors before the diagnosis of Huntington's disease and their relationship to markers of disease progression: evidence of early lack of awareness. J Neuropsychiatry Clin Neurosci 2010;22:196-207.
43. Poudel GR, Egan GF, Churchyard A, Chua P, Stout JC, Georgiou-Karistianis N. Abnormal synchrony of resting state networks in premanifest and symptomatic Huntington disease: the IMAGE-HD study. J Psychiatry Neurosci 2014;39:87-96.
44. Naarding P, Jaanzing JG, Eling P, van der Werf S, Kremer B. Apathy Is Not Depression in Huntington's Disease. J Neuropsychiatry Clin Neurosci 2009;21:266-270.
45. Blackwell AD, Paterson NS, Barker RA, Robbins TW, Sahakian BJ. The effects of modafinil on mood and cognition in Huntington's disease. Psychopharmacology (Berl) 2008;199:29-36.
46. Watson D, Wu KD. Development and validation of the Schedule of Compulsions, Obsessions, and Pathological Impulses (SCOPI). Assessment 2005;12:50-65.
47. Gray MA, Egan GF, Ando A, et al. Prefrontal activity in Huntington's disease reflects cognitive and neuropsychiatric disturbances: the IMAGE-HD study. Exp Neurol 2013;239:218-228.
48. Dominguez DJ, Egan GF, Gray MA, et al. Multi-modal neuroimaging in premanifest and early Huntington's disease: 18 month longitudinal data from the IMAGE-HD study. PLoS One 2013;8:e74131.
49. Beglinger LJ, Paulsen JS, Watson DB, et al. Obsessive and compulsive symptoms in prediagnosed Huntington's disease. J Clin Psychiatry 2008;69:1758-1765.
50. Snaith RP, Constantopoulos AA, Jardine MY, McGuffin P. A clinical scale for the self-assessment of irritability. Br J Psychiatry 1978;132:164-171.
51. Craig KJ, Hietanen H, Markova IS, Berrios GE. The Irritability Questionnaire: a new scale for the measurement of irritability. Psychiatry Res 2008;159:367-375.
52. Vassos E, Panas M, Kladi A, Vassilopoulos D. Higher levels of extroverted hostility detected in gene carriers at risk for Huntington's disease. Biol Psychiatry 2007;62:1347-1352.
53. Sprengelmeyer R, Orth M, Muller HP, et al. The neuroanatomy of subthreshold depressive symptoms in Huntington's disease: a combined diffusion tensor imaging (DTI) and voxel-based morphometry (VBM) study. Psychol Med 2014;44:1867-1878.
54. Tippett LJ, Waldvogel HJ, Thomas SJ, et al. Striosomes and mood dysfunction in Huntington's disease. Brain 2007;130:206-221.
55. Rees EM, Farmer R, Cole JH, et al. Cerebellar abnormalities in Huntington's disease: a role in motor and psychiatric impairment? Mov Disord 2014;29:1648-1654.
56. Burns A, Folstein S, Brandt J, Folstein M. Clinical assessment of irritability, aggression, and apathy in Huntington and Alzheimer disease. J Nerv Ment Dis 1990;178:20-26.
57. DudokdeWit AC, Tibben A, Duivenvoorden HJ, Niermeijer MF, Passchier J. Predicting adaptation to presymptomatic DNA testing for late onset disorders: who will experience distress? Rotterdam Leiden Genetics Workgroup. J Med Genet 1998;35:745-754.
58. Lundin A, Dietrichs E, Haghighi S, et al. Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease. Clin Neuropharmacol 2010;33:260-264.
59. de Yebenes JG, Landwehrmeyer B, Squitieri F, et al. Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2011;10:1049-1057.
60. Dale M, Maltby J, Martucci R, Shimozaki S. Factor analysis of the hospital anxiety and depression scale among a Huntington's disease population. Mov Disord 2015;30:1954-1960.
61. Craufurd D, Thompson JC, Snowden JS. Behavioral changes in Huntington Disease. Neuropsychiatry Neuropsychol Behav Neurol 2001;14:219-226.
62. Callaghan J, Stopford C, Arran N, et al. Reliability and factor structure of the Short Problem Behaviors Assessment for Huntington's disease (PBA-s) in the TRACK-HD and REGISTRY studies. J Neuropsychiatry Clin Neurosci 2015;27:59-64.
63. National Institute of Neurological Disorders and Stroke (NINDS). NINDS CDE Notice of Copyright, Problem Begaviors Assessment-short form (PBA-s). Available at: https://commondataelements.ninds.nih.gov/Doc/NOC/Problem_Behavior_Assessment_NOC_Email.pdf. Accessed November 12, 2015.
64. Tabrizi SJ, Langbehn DR, Leavitt BR, et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 2009;8:791-801.
65. Justo D, Charles P, Daunizeau J, et al. Is non-recognition of choreic movements in Huntington disease always pathological? Neuropsychologia 2013;51:748-759.
66. Delmaire C, Dumas EM, Sharman MA, et al. The structural correlates of functional deficits in early huntington's disease. Hum Brain Mapp 2013;34:2141-2153.
67. Kingma EM, van Duijn E, Timman R, van der Mast RC, Roos RA. Behavioural problems in Huntington's disease using the Problem Behaviours Assessment. Gen Hosp Psychiatry 2008;30:155-161.
68. Kulisevsky J, Litvan I, Berthier ML, Pascual-Sedano B, Paulsen JS, Cummings JL. Neuropsychiatric assessment of Gilles de la Tourette patients: comparative study with other hyperkinetic and hypokinetic movement disorders. Mov Disord 2001;16:1098-1104.
69. Litvan I, Paulsen JS, Mega MS, Cummings JL. Neuropsychiatric assessment of patients with hyperkinetic and hypokinetic movement disorders. Arch Neurol 1998;55:1313-1319.
70. Paulsen JS, Ready RE, Hamilton JM, Mega MS, Cummings JL. Neuropsychiatric aspects of Huntington's disease. J Neurol Neurosurg Psychiatry 2001;71:310-314.
71. Levy ML, Cummings JL, Fairbanks LA, et al. Apathy is not depression. J Neuropsychiatry Clin Neurosci 1998;10:314-319.
72. Curtis A, Mitchell I, Patel S, Ives N, Rickards H. A pilot study using nabilone for symptomatic treatment in Huntington's disease. Mov Disord 2009;24:2254-2259.
73. Group HS. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 1996;11:136-142.
74. Jankovic J, Beach J, Ashizawa T. Emotional and functional impact of DNA testing on patients with symptoms of Huntington's disease. J Med Genet 1995;32:516-518.
75. Marder K, Zhao H, Myers RH, et al. Rate of functional decline in Huntington's disease. Huntington Study Group. Neurology 2000;54:452-458.
76. Peavy GM, Jacobson MW, Goldstein JL, et al. Cognitive and functional decline in Huntington's disease: dementia criteria revisited. Mov Disord 2010;25:1163-1169.
77. Beglinger LJ, Duff K, Allison J, et al. Cognitive change in patients with Huntington disease on the Repeatable Battery for the Assessment of Neuropsychological Status. J Clin Exp Neuropsychol 2010;32:573-578.
78. Meyer C, Landwehrmeyer B, Schwenke C, Doble A, Orth M, Ludolph AC. Rate of change in early Huntington's disease: a clinicometric analysis. Mov Disord 2012;27:118-124.
79. Wetzel HH, Gehl CR, Dellefave-Castillo L, Schiffman JF, Shannon KM, Paulsen JS. Suicidal ideation in Huntington disease: the role of comorbidity. Psychiatry Res 2011;188:372-376.
80. Epping EA, Mills JA, Beglinger LJ, et al. Characterization of depression in prodromal Huntington disease in the neurobiological predictors of HD (PREDICT-HD) study. J Psychiatr Res 2013;47:1423-1431.
81. Hamilton JM. Rate and correlates of weight change in Huntington's disease. Journal of Neurology, Neurosurgery & Psychiatry 2004;75:209-212.
82. Rickards H, De Souza J, van Walsem M, et al. Factor analysis of behavioural symptoms in Huntington's disease. J Neurol Neurosurg Psychiatry 2011;82:411-412.
83. Wing J. SCAN and the PSE tradition. Soc Psychiatry Psychiatr Epidemiol 1996;31:50-54.
84. Pflanz S, Besson JA, Ebmeier KP, Simpson S. The clinical manifestation of mental disorder in Huntington's disease: a retrospective case record study of disease progression. Acta Psychiatr Scand 1991;83:53-60.
85. Mayberg HS, Starkstein SE, Peyser CE, Brandt J, Dannals RF, Folstein SE. Paralimbic frontal lobe hypometabolism in depression associated with Huntington's disease. Neurology 1992;42:1791-1797.
86. Wong MT, Chang PC, Yu YL, Chan YW, Chan V. Psychosocial impact of Huntington's disease on Hong Kong Chinese families. Acta Psychiatr Scand 1994;90:16-18.
87. Reilmann R, Leavitt BR, Ross CA. Diagnostic criteria for Huntington's disease based on natural history. Mov Disord 2014;29:1335-1341.